Rapid Research in Diagnostics Development for TB Network

We will evaluate tests intended to make culture more sensitive, faster, and have less contamination.

We will evaluate new staining techniques or visualization methods to increase the sensitivity of smear microscopy.

We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

We will evaluate urine LAM assays incorporating techniques such as analyte concentration, higher sensitivity or specificity antibodies, or enhanced visualization to improve LAM detection.

We will evaluate assays measuring host immune response parameters intended for use at near point of care or point of care.

We will evaluate assays assessing volatile organic compounds or exhaled breath condensate for near point of care of point of care detection of TB.

We will evaluate AI-based algorithms evaluating images (chest x-ray, ultrasound) or sounds (cough sounds, lung sounds) including an Infrasound-to-ultrasound e-stethoscope (Level 42 AI, USA).

We will evaluate assays using phages to lyse mycobacterial cells for detection of DNA or antigens.

We will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.

We will evaluate targeted and whole genome sequencing assays.